25 Year Incidence of De Novo Malignancies After Liver Transplantation: A Single-Center Analysis of Risk Factors and Mortality in 1179 Patients.

2014 ◽  
Vol 98 ◽  
pp. 173
Author(s):  
S. Rademacher ◽  
M. Hippler-Benscheidt ◽  
R. Neuhaus ◽  
T. Denecke ◽  
G. Puhl ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
De Novo ◽  
Single Center

scholarly journals Weight Gain and De Novo Metabolic Disorders after Liver Transplantation

Nutrients ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 3015 ◽  
Author(s):  
Barbara Lattanzi ◽  
Daria D’Ambrosio ◽  
Daniele Tavano ◽  
Demis Pitoni ◽  
Gianluca Mennini ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Liver Transplantation ◽  
Retrospective Study ◽  
Liver Disease ◽  
Metabolic Disorders ◽  
De Novo ◽  
Metabolic Abnormalities ◽  
Single Center

The development of nutritional and metabolic abnormalities represents an important burden in patients after liver transplantation (LT). Our study aimed at evaluating the incidence, time of onset, and risk factors for nutritional and metabolic abnormalities in patients after LT. The study was a single-center retrospective study. Consecutive patients undergoing elective LT from 2000 to 2016 were enrolled. The presence of at least two among arterial hypertension (AH), diabetes mellitus (DM), dyslipidemia, and obesity (BMI ≥ 30 Kg/m2) was utilized to define patients with the metabolic disorder (MD). Three hundred and fifteen patients were enrolled; the median age was 56 years (68% males). Non-alcoholic steatohepatitis (NASH) was the origin of liver disease in 10% of patients. During follow-up, 39% of patients developed AH, 18% DM, and 17% dyslipidemia. Metabolic disorders were observed in 32% of patients. The NASH etiology (OR: 6.2; CI 95% 0.5–3; p = 0.003) and a longer follow-up (OR: 1.2; CI 95% 0.004–0.02; p = 0.002) were associated with de novo MD. In conclusion, nutritional and metabolic disorders are a frequent complication after LT, being present in up to one-third of patients. The NASH etiology and a longer distance from LT are associated with de novo MD after LT.

The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients

2017 ◽  
Vol 23 (11) ◽  
pp. 1404-1414 ◽  
Author(s):  
Sebastian Rademacher ◽  
Daniel Seehofer ◽  
Dennis Eurich ◽  
Wenzel Schoening ◽  
Ruth Neuhaus ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
De Novo ◽  
Single Center

scholarly journals A207 DE NOVO DONOR-SPECIFIC ANTIBODY FORMATION IN LIVER TRANSPLANTS: RISK FACTORS FOR DEVELOPMENT AND IMPACT ON GRAFT SURVIVAL.

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 236-237
Author(s):  
C Wang ◽  
A J Montano-Loza ◽  
P M Campbell ◽  
V Bain
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
Liver Disease ◽  
Organ Transplantation ◽  
Graft Survival ◽  
Patient Survival ◽  
De Novo ◽  
Single Center ◽  
Liver Transplants ◽  
Post Transplant

Abstract Background Antibody mediated rejection (AMR) is an area of great importance in solid organ transplantation. Donor-specific antibodies (DSA) have emerged as relevant biomarkers in predicting graft function and survival. DSA detected post-transplant may either be preformed or de novo and emerging evidence suggests de novo DSA, in particular, is associated with inferior graft outcomes. In contrast to the clear role that AMR plays in renal and thoracic organ transplantation, its importance in liver transplants remains controversial. Aims The aim of this study was to determine the risk factors associated with de novo DSA formation and to evaluate its role in determining clinical outcomes after liver transplantation. Methods This single-center retrospective study compiled data on liver transplants performed between 2005 and 2019 in Edmonton, Canada. Data collected from medical charts included gender, age at transplant, reason for transplant, and immunosuppressive regimens, among several others. The presence of DSA was determined by single antigen flow beads until 2009 and by Luminex thereafter. Potential predictors of DSA formation were evaluated using Cox proportional hazard models. Graft survival estimates were obtained using the Kaplan-Meier method and comparisons between patient groups were conducted using the log-rank test. Results Between 2005–2019, 131 patients had measurements of DSA both before and after liver transplantation. In this cohort, 17 patients (13%) tested negative on DSA screening before transplant but developed new antibodies against either Class I or Class II molecules post-transplant. Risk factor analysis revealed transplants performed in the setting of autoimmune liver disease (PSC, PBC, and autoimmune hepatitis) had higher risks of developing de novo DSA post-transplant (p=0.002. See Table 1). Graft survival probability at 5- and 10-years was 72% and 61% in those with de novo DSA formation, compared to 93% and 89% in patients without de novo DSA formation (p=0.04. See Figure 1). Overall patient survival was similar between the two groups. Conclusions In this single-center study, a transplant done in the setting of autoimmune liver disease had a higher risk of de novo DSA formation. Furthermore, de novo DSA formation lead to a decreased graft survival time in liver transplant patients but overall patient survival was not significantly decreased. A standard approach to DSA monitoring, especially in high risk populations, is required to better understand its prevalence and impact in liver transplantation. Funding Agencies None

De Novo Tumours after Liver Transplantation: Does Prevalence Increase with Aging? A Single Center Experience

2012 ◽  
Vol 94 (10S) ◽  
pp. 602
Author(s):  
M. G. Fernandez ◽  
D. Loredo ◽  
F. Gruz ◽  
S. Raffa ◽  
S. Yantorno ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
De Novo ◽  
Single Center ◽  
Single Center Experience

Risk factors for hepatitis B virus recurrence after living donor liver transplantation: A 17-year experience at a single center

2015 ◽  
Vol 45 (12) ◽  
pp. 1203-1210 ◽  
Author(s):  
Sung Kwan Bae ◽  
Shinji Shimoda ◽  
Toru Ikegami ◽  
Tomoharu Yoshizumi ◽  
Norifumi Harimoto ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Single Center ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
B Virus

Pleural Effusions Following Liver Transplantation: A Single-Center Experience

2020 ◽  
pp. 088506662093244
Author(s):  
Justin K. Lui ◽  
Lidia Spaho ◽  
Shahrad Hakimian ◽  
Michael Devine ◽  
Rosa Bui ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
Liver Transplant ◽  
Hospital Length Of Stay ◽  
Transplant Recipients ◽  
Single Center ◽  
Pleural Effusions ◽  
Post Transplantation ◽  
Significant Difference ◽  
Liver Transplant Recipients

Introduction: This was a single-center retrospective study to evaluate incidence, prognosis, and risk factors in patients with postoperative pleural effusions, a common pulmonary complication following liver transplantation. Methods: A retrospective review was performed on 374 liver transplantation cases through a database within the timeframe of January 1, 2009 through December 31, 2015. Demographics, pulmonary and cardiac function testing, laboratory studies, intraoperative transfusion/infusion volumes, postoperative management, and outcomes were analyzed. Results: In the immediate postoperative period, 189 (50.5%) developed pleural effusions following liver transplantation of which 145 (76.7%) resolved within 3 months. Those who developed pleural effusions demonstrated a lower fibrinogen (149.6 ± 66.3 mg/dL vs 178.4 ± 87.3 mg/dL; P = .009), total protein (5.8 ± 1.0 mg/dL vs 6.1 ± 1.2 mg/dL; P = .04), and hemoglobin (9.8 ± 1.8 mg/dL vs 10.3 ± 1.9 mg/dL; P = .004). There was not a statistically significant difference in 1-year all-cause mortality and in-hospital mortality between liver transplant recipients with and without pleural effusions. Liver transplant recipients who developed pleural effusions had a longer hospital length of stay (16.4 ± 10.9 days vs 14.0 ± 16.5 days; P = .1), but the differences were not statistically significant. However, there was a significant difference in tracheostomy rates (11.6% vs 5.4%; P = .03) in recipients who developed pleural effusions compared to recipients who did not. Conclusions: In summary, pleural effusions are common after liver transplantation and are associated with increased morbidity. Pre- and intraoperative risk factors can offer both predictive and prognostic value for post-transplantation pleural effusions. Further prospective studies will be needed to further evaluate the relevance of these findings to limit instances of postoperative pleural effusions.

De Novo Malignancies After Liver Transplantation With 14 Cases at a Single Center

2015 ◽  
Vol 47 (8) ◽  
pp. 2483-2487 ◽  
Author(s):  
Z.-N. Liu ◽  
W.-T. Wang ◽  
L.-N. Yan
Keyword(s):  
Liver Transplantation ◽  
De Novo ◽  
Single Center

A single-institution survey of de novo secondary malignancies in patients occurring after orthotropic liver transplantation.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 297-297
Author(s):  
Quentin Gillebert ◽  
Mohamed Bouattour ◽  
Francois Durand ◽  
Claire Francoz ◽  
Valerie Paradis ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
De Novo ◽  
Secondary Malignancy ◽  
Prior History ◽  
Lung Cancers ◽  
History Of ◽  
Independent Risk Factors ◽  
De Novo Cancer ◽  
Tumor Types

297 Background: We aim to evaluate in our institution the incidence of de novo malignancies following orthotopic liver transplantation (OLT) and their impact the prognosis of patients (pts). Methods: Pts treated with OLT from August 1991 To March 2009 were considered in this analysis. All pts data had been prospectively recorded in the database of French “Bio-medecine Agence”. Pts were considered for this analysis only if they survived at least 3-months after. Occurrence of de novo malignancies we analyzed and additional data (including immunosuppressive profile, type of cancer, potential independent risk factors of cancers, prognosis and the influence of immunosuppression protocols or risk factors on occurrence of cancers) were collected in patients who developed secondary cancers. Results: A total of 833 patients who underwent OLT were considered for this analysis. With a median follow-up of 7.9 years, 72 pts developed 92 de novo malignancies. The overall incidence of cancers in our population was 10.4% occurring with a median time of 6.1 years following OLT. Sixteen pts developed 2 different types of cancer and 2 pts had more than 3 tumor types. Before 12/1998, immunosuppression was primarily based on cyclosporine, steroids and/or azathiopirine, and since 01/1999 was switched to tacrolimus. Incidence of cancers regarding these two periods is summarized in the table. Before 1998, only 3 pts (17.6%) with secondary cancer had prior history of alcoholism and/or smoking compared to 27 pts (50%) after 1999. Thirty one deaths were observed and the median overall survival (OS) after the time of diagnosis of secondary malignancy was 5.62 years. Conclusions: The risk of de novo cancer after OLT is similar to reported series. History of smoking and alcohol use, increase the incidence of de novo malignancies especially head and neck and lung cancers however, immunosuppression type may not interfere with this risk. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document